(Redirected from Volitinib)Jump to navigation Jump to search
|Chemical and physical data|
|Molar mass||345.370 g·mol−1|
|3D model (JSmol)|
Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by AstraZeneca. It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma.
- "Savolitinib" (PDF). Statement on a Nonproprietary Name Adopted by the USAN Council. American Medical Association. 26 October 2016.
- "Savolitinib - AstraZeneca/Hutchison China MediTech Limited". AdisInsight. Springer Nature Switzerland AG.